牛贝消核提取物血清药物化学的初步研究

doi:10.19982/j.issn.1000-6621.20210710

中国防痨杂志 ›› 2022, Vol. 44 ›› Issue (5): 455-459.doi: 10.19982/j.issn.1000-6621.20210710

牛贝消核提取物血清药物化学的初步研究

段利瑶¹^,², 凌彦博¹, 梁艳¹, 史迎昌¹, 王兰¹, 赵冠人³, 刘军⁴, 郑越¹(), 吴雪琼¹()

¹中国人民解放军总医院第八医学中心/结核病医学部/全军结核病研究所/全军结核病防治重点实验室/结核病诊疗新技术北京市重点实验室,北京 100091
²河北省沧州中西医结合医院西药学部,沧州 061001
³中国人民解放军总医院第八医学中心药剂科,北京 100091
⁴广东奇方药业有限公司, 广州510075

收稿日期:2021-12-18 出版日期:2022-05-10 发布日期:2022-05-04
通信作者: 郑越,吴雪琼 E-mail:zhengy309@126.com;xueqiongwu@139.com
基金资助:
北京市科学技术委员会G20工程支撑保障专项(Z171100001717010);北京市“十病十药”研发专项(Z141100002214002)

Preliminary study on serum pharmacochemistry of Niubeixiaohe extract

DUAN Li-yao¹^,², LING Yan-bo¹, LIANG Yan¹, SHI Ying-chang¹, WANG Lan¹, ZHAO Guan-ren³, LIU Jun⁴, ZHENG Yue¹(), WU Xue-qiong¹()

¹Tuberculosis Prevention and Control Key Laboratory, Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Tuberculosis Research Institute, Senior Department of Tuberculosis, the 8th Medical Center of Chinese PLA General Hospital, Beijing 100091, China
²Department of Pharmacy, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine of Hebei Province, Cangzhou 061001, China
³Department of Pharmacy, the 8th Medical Center of Chinese PLA General Hospital, Beijing 100091, China
⁴Guangdong Qifang Pharmaceutical Co., Ltd., Guangzhou 510075, China

Received:2021-12-18 Online:2022-05-10 Published:2022-05-04
Contact: ZHENG Yue,WU Xue-qiong E-mail:zhengy309@126.com;xueqiongwu@139.com
Supported by:
G20 Engineering Support and Guarantee Special Project of Beijing Municipal Science and Technology Commission(Z171100001717010);Beijing “Ten Diseases and Ten Medicines” Research and Development Special Project(Z141100002214002)

摘要/Abstract

摘要：

目的: 对抗结核中药牛贝消核提取物进行血清药物化学初步研究,通过分析入血成分,探讨牛贝消核发挥药效的物质基础。方法: 2018年4月至2019年6月在中国人民解放军总医院第八医学中心全军结核病研究所制备桔梗、白及、鱼腥草和牛蒡子标准品溶液及牛贝消核供试品;55只小鼠随机分为11组,每组5只:1~5组为牛贝消核提取物组,每只小鼠每天给予 1.25mg/g牛贝消核提取物灌胃;6~10组为牛蒡苷组,每只小鼠每天给予 0.3mg/g牛蒡苷灌胃;11组为空白对照组,给予蒸馏水灌胃;连续灌胃7d。于末次给药后0.5、1、2、4、6h小鼠眼眶后静脉丛取血,制备血清供试品溶液。采用高效液相色谱法(high-performance liquid chromatography, HPLC)分析各中药标准品、牛贝消核提取物供试品及各组小鼠给药后血清供试品溶液,分析色谱图中各物质保留时间;然后参照对照品初步鉴定牛贝消核提取物的入血成分。结果: 通过牛贝消核提取物和各药材标准品重叠色谱图中可以看出,牛贝消核提取物保留时间为7.1min处的色谱峰所对应的物质来源于桔梗,保留时间为13.5min、15.5min、21.2min处的色谱峰所对应的物质来源于白及,保留时间为16.3min的色谱峰所对应的物质来源于牛蒡子,并进一步鉴定为牛蒡苷化合物。牛贝消核提取物和牛蒡苷给药后血清样本与空白血清比较,均在17.5~22.5min发现有吸收峰。结论: HPLC分析可作为牛贝消核中桔梗、白及、鱼腥草和牛蒡子提取的质量控制方法,检出的牛贝消核提取物血中移行成分可能是牛蒡苷代谢产物,其余药效成分入血微量未检出。

关键词: 中药复方, 牛贝消核, 血清药物化学, 色谱法,高效液相, 抗结核药

Abstract:

Objective: Preliminary research on serum pharmacochemistry was carried out on the extract of anti-tuberculosis Chinese medicine Niubeixiaohe, and the material basis of Niubeixiaohe’s efficacy was discussed by analyzing the blood components. Methods: From April 2018 to June 2019, the standard solutions of Radix Platycodonis, Rhizoma Bletillae,Herba Houttuyniae, Fructus Arctii and the sample of Niubeixiaohe were prepared at the Tuberculosis Research Institute, the Eighth Medical Center of Chinese PLA General Hospital. 55 mice were randomly divided into 11 groups with 5 mice each group: Group 1 to 5 named Niubeixiaohe extract group were given Niubeixiaohe extract 1.25 mg·g^-1·d^-1; Group 6 to 10 named arctiin group were given arctiin 0.3 mg·g^-1·d^-1; Group 11 was the blank control group, which was given distilled water. The mice were gavaged continuously for 7 days. Blood was collected from the retroorbital venous plexus of mice at 0.5, 1, 2, 4, and 6 hours after the last administration to prepare the serum solution. The retention time of each substance in the chromatogram of the standard of traditional Chinese medicine, Niubeixiaohe extract and the serum sample solution of mice in each group after administration was analyzed by HPLC. The constituents absorbed into the blood of Niubeixiaohe extract were preliminarily identified with the reference substance. Results: The overlapping chromatograms of Niubeixiaohe extract and each medicinal standard showed that the substance corresponding to the chromatographic peak at the retention time of 7.1 min was derived from Radix Platycodonis, and the substance corresponding to the chromatographic peak at the retention time of 13.5 min, 15.5 min and 21.2 min was derived from Rhizoma Bletillae, and the substance corresponding to the chromatographic peak at the retention time of 16.3 min was derived from Fructus Arctii, which was further identified as arctiin compound. Compared with the blank control serum, the serum samples after the administration of Niubeixiaohe extract and arctiin was found the absorption peaks in 17.5-22.5 min. Conclusion: HPLC can be used as a quality control method for the extraction of Radix Platycodonis, Rhizoma Bletillae, Herba Houttuyniae, and Fructus Arctii in Niubeixiaohe. The detected constituents absorbed into the blood of Niubeixiaohe extract may be arctiin metabolites, and the trace amount of other pharmacodynamic components into the blood was not detected.

Key words: Traditional Chinese medicine compound, Niubeixiaohe, Serum pharmacochemistry, High performance liquid chromatography, Antituberculosis agents

中图分类号:

R917

段利瑶, 凌彦博, 梁艳, 史迎昌, 王兰, 赵冠人, 刘军, 郑越, 吴雪琼. 牛贝消核提取物血清药物化学的初步研究[J]. 中国防痨杂志, 2022, 44(5): 455-459. doi: 10.19982/j.issn.1000-6621.20210710

DUAN Li-yao, LING Yan-bo, LIANG Yan, SHI Ying-chang, WANG Lan, ZHAO Guan-ren, LIU Jun, ZHENG Yue, WU Xue-qiong. Preliminary study on serum pharmacochemistry of Niubeixiaohe extract[J]. Chinese Journal of Antituberculosis, 2022, 44(5): 455-459. doi: 10.19982/j.issn.1000-6621.20210710

图/表 4

参考文献 16

[1]	赵高琼, 任波, 董小萍, 等. 川贝母研究现状. 中药与临床, 2012, 3(6): 59-64. doi: CNKI:SUN:LCZY.0.2012-06-023. doi: CNKI:SUN:LCZY.0
[2]	He X, Wang X, Fang J, et al. Bletilla striata: Medicinal uses, phytochemistry and pharmacological activities. J Ethnopharmacol, 2017, 195:20-38. doi: 10.1016/j.jep.2016.11.026. doi: 10.1016/j.jep.2016.11.026 URL
[3]	国家药典委员会. 中华人民共和国药典一部. 北京: 中国医药科技出版社, 2015.
[4]	孙晖, 吴泽明, 吕海涛, 等. 中药及其复方的体内代谢研究现状与未来发展. 世界科学技术-中医药现代化, 2006, 8(6): 1-6. doi: 10.11842/wst.2006.6. doi: 10.11842/wst.2006.6
[5]	王喜军. 中药及中药复方的血清药物化学研究. 世界科学技术·中药现代化, 2002, 4(2): 1-4. doi: 10.3969/j.issn.1674-3849.2002.02.001. doi: 10.3969/j.issn.1674-3849.2002.02.001
[6]	陈卓, 潘明佳, 邢雪飞, 等. 血清药物化学在中药及其复方药效物质基础研究中的进展. 药物评价研究, 2016, 39(1): 143-147. doi: 10.7501/j.issn.1674-6376.2016.01.027. doi: 10.7501/j.issn.1674-6376.2016.01.027
[7]	王红波. 菊苣降尿酸有效成分的血清药物化学研究. 北京: 北京中医药大学, 2016.
[8]	马飞祥, 薛培凤, 王媛媛, 等. 中药血清药物化学研究进展. 中国中药杂志, 2017, 42(7): 1265-1270. doi: 10.19540/j.cnki.cjcmm.20170224.010. doi: 10.19540/j.cnki.cjcmm.20170224.010
[9]	Chen HG, Zhou X, Zhao Y, et al. HPLC-DAD-ELSD combined pharmacodynamics and serum medicinal chemistry for quality assessment of Huangqi granule. PLoS One, 2015, 10(4): e0123176. doi: 10.1371/journal.pone.0123176. doi: 10.1371/journal.pone.0123176 URL
[10]	Zhang C, Lian R, Mahmoodurrahman M, et al. Serum pharmacochemistry for tracking bioactive components by UPLC-Q-TOF-MS/MS combined chromatographic fingerprint for quality assessment of Sanziguben Granule. J Chromatogr B Analyt Technol Biomed Life Sci, 2016, 1029/1030:128-136. doi: 10.1016/j.jchromb.2016.07.022. doi: 10.1016/j.jchromb.2016.07.022 URL
[11]	He F, Dou DQ, Sun Y, et al. Determination of Arctiin in rat plasma by HPLC method and its application to pharmacokinetic studies. J Med Plants Research, 2011, 5(4): 549-557. doi: 10.1007/BF00989335. doi: 10.1007/BF00989335
[12]	王宇卿, 李淑娇, 庄果. 基于HPLC-Q-TOF/MS法的鬼针草血清药物化学探究. 中成药, 2020, 42(11): 3074-3078. doi: 10.3969/j.issn.1001-1528.2020.11.048. doi: 10.3969/j.issn.1001-1528.2020.11.048
[13]	胥秀英, 郑一敏, 傅善权, 等. 牛蒡子苷在小鼠体内的分布状态及药代动力学研究. 时珍国医国药, 2006, 17(5): 698-699. doi: 10.3969/j.issn.1008-0805.2006.05.008. doi: 10.3969/j.issn.1008-0805.2006.05.008
[14]	Wang W, Pan Q, Han XY, et al. Simultaneous determination of arctiin and its metabolites in rat urine and feces by HPLC. Fitoterapia, 2013, 86: 6-12. doi: 10.1016/j.fitote.2013.01.016. doi: 10.1016/j.fitote.2013.01.016 pmid: 23380537
[15]	郑一敏, 蔡绍皙, 胥秀英, 等. 牛蒡子苷代谢动力学与分布研究. 中国现代应用药学杂志, 2006, 23(4): 265-267. doi: 10.3969/j.issn.1007-7693.2006.04.001. doi: 10.3969/j.issn.1007-7693.2006.04.001
[16]	王潞, 赵烽, 刘珂. 牛蒡子苷及牛蒡子苷元的药理作用研究进展. 中草药, 2008, 39(3): 467-470. doi: 10.3321/j.issn:0253-2670.2008.03.04. doi: 10.3321/j.issn:0253-2670.2008.03.04

牛贝消核提取物血清药物化学的初步研究

Preliminary study on serum pharmacochemistry of Niubeixiaohe extract

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 4

参考文献 16

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	梁丽, 邹莉萍, 谢芳晖, 陈晴, 吴桂辉. 抗结核药物相关急性肝衰竭患儿三例并文献复习[J]. 中国防痨杂志, 2022, 44(4): 343-348.
[2]	安军, 逄宇. 抗结核新药的临床应用:新希望与新挑战[J]. 中国防痨杂志, 2022, 44(3): 205-208.
[3]	陆霓虹, 沈凌筠, 刘洪璐, 陈杨君, 杜映荣. 基质金属蛋白酶类水平与抗结核药物性导致肝损伤的相关性分析[J]. 中国防痨杂志, 2022, 44(2): 164-168.
[4]	祁雪婷, 陆宇, 陈效友. 抗结核新药药效学特点及相互作用研究[J]. 中国防痨杂志, 2021, 43(9): 965-969.
[5]	姚蓉, 陆宇. 抗结核药物早期杀菌活性研究及进展[J]. 中国防痨杂志, 2021, 43(7): 724-728.
[6]	郑璐瑶, 陆宇, 陈效友. 非结核分枝杆菌肺病治疗药物研发的现状与挑战[J]. 中国防痨杂志, 2021, 43(7): 729-734.
[7]	戈启萍, 杜建, 舒嶶, 马艳, 马丽萍, 赵彩燕, 陈瑜晖, 张立杰, 黄学锐, 韩喜琴, 陈盛玉, 王飞, 李波, 曹文利, 刘倩颖, 陈东进, 石莲, 王鑫, 黎友伦, 杨尚鹏, 彭章丽, 吴超, 欧阳兵, 王芙蓉, 李钋, 吴湘, 席秀娥, 冷学艳, 张海晴, 李华, 李鹃, 杨澄清, 张朋, 崔洪哲, 谢莉, 刘宇红, 李亮, 高微微. 优化方案治疗复治药物敏感肺结核的疗效评价[J]. 中国防痨杂志, 2021, 43(4): 328-334.
[8]	刘海婷, 陆宇. 抗结核药物组合药效筛选研究进展[J]. 中国防痨杂志, 2021, 43(4): 404-408.
[9]	刘鑫, 郭乐, 仵倩红. 抗结核药品导致严重骨髓抑制一例并文献复习[J]. 中国防痨杂志, 2021, 43(4): 413-418.
[10]	曹鑫宇, 薛秒, 文艳, 刘莉. 抗结核药物性肝损伤易感基因研究进展[J]. 中国防痨杂志, 2021, 43(2): 190-193.
[11]	阮洪云, 李琦, 陈效友, 段鸿飞, 郭超, 操敏, 梁清涛, 王志茹, 杨扬, 孙桂新, 李华, 邓玲, 绍玲玲, 邢维祥, 张芸, 杨新婷. 结核性胸膜炎患者化疗时是否加用糖皮质激素对肺功能动态变化的对比研究[J]. 中国防痨杂志, 2021, 43(1): 58-65.
[12]	段鸿飞, 初乃惠. 抗结核药品临床试验疗效评价指标的研究进展[J]. 中国防痨杂志, 2021, 43(1): 96-99.
[13]	张静, 陈曦, 王彬, 付雷, 陆宇, 陈效友. 改良单叠氮丙啶-荧光定量PCR法的建立及其检测抗结核药物活性的价值[J]. 中国防痨杂志, 2020, 42(5): 472-480.
[14]	高天慧,舒薇,高静韬,陆宇,李琦. 254例耐药肺结核患者克拉霉素耐药情况及影响因素分析[J]. 中国防痨杂志, 2020, 42(3): 259-265.
[15]	陈浩,武楠楠,胡文辉,杨忠金. 抗结核药物作用新靶点及其研究进展[J]. 中国防痨杂志, 2020, 42(3): 286-292.